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Insulin stimulates glucose uptake through the
membrane translocation of GLUT4 and GLUT1. Per-
oxisome proliferator-activated receptor g (PPARg)
enhances insulin sensitivity. Here, we demonstrate
that insulin stimulates GLUT4 and GLUT1 transloca-
tion, and glucose uptake, by activating the signaling
pathway involving nicotinic acid adenine dinucleo-
tide phosphate (NAADP), a calcium mobilizer, in
adipocytes. We also demonstrate that PPARgmedi-
ates insulin sensitization by enhancing NAADP
production through upregulation of CD38, the only
enzyme identified for NAADP synthesis. Insulin
produced NAADP by both CD38-dependent and
-independent pathways, whereas PPARg produced
NAADP by CD38-dependent pathway. Blocking the
NAADP signaling pathway abrogated both insulin-
stimulated and PPARg-induced GLUT4 and GLUT1
translocation, thereby inhibiting glucose uptake.
CD38 knockout partially inhibited insulin-stimulated
glucose uptake. However, CD38 knockout com-
pletely blocked PPARg-induced glucose uptake in
adipocytes and PPARg-mediated amelioration of
glucose tolerance in diabetic mice. These results
demonstrated that the NAADP signaling pathway is
a critical molecular target for PPARg-mediated
insulin sensitization.INTRODUCTION
The main function of insulin is to control glucose homeostasis
by stimulating glucose uptake in peripheral tissues, which
primarily results from glucose transporter 4 (GLUT4) transloca-
tion. Insulin signaling consists of activation of insulin receptor
(IR) tyrosine kinase activity, autophosphorylation of its receptor,
and phosphorylation of several substrates (Lizcano and Alessi,Cell Re2002). This series of changes results in subsequent recruitment
of downstream signaling molecules, including adapters, protein
serine/threonine kinases, phosphoinositide kinases, and ex-
change factors (Lizcano and Alessi, 2002). Although the
signaling molecules that interact with the activated IR have
been well characterized, the link between the insulin signaling
pathway and GLUT4 translocation is still unknown.
Peroxisome proliferator-activated receptor g (PPARg), a
nuclear receptor superfamily of ligand-dependent transcription
factors, forms a heterodimer with retinoic X receptor-a (RXRa)
and regulates transcription of target genes involved in fatty
acid uptake and storage, adipocyte differentiation, inflammation,
and vascular function (Dreyer et al., 1992; Kliewer et al., 1994;
Tontonoz et al., 1994; Tontonoz et al., 1997). The typical binding
site for the PPARg-RXRa heterodimer, the PPAR responsive
element (PPRE), is a direct repeat of AGGTCA spaced by one
nucleotide (Berger et al., 1996; Kliewer et al., 1992). Synthetic
thiazolidinedione derivatives, such as troglitazone and rosiglita-
zone, act as exogenous specific PPARg ligands and enhance
PPARg transcriptional activity (Lehmann et al., 1995). The exog-
enous potent PPARg ligands increase insulin sensitivity in
muscle and adipose tissues, and some of them are used for
the treatment of type 2 diabetes (Saltiel and Olefsky, 1996).
However, the mechanism by which PPARg agonists increase
glucose uptake in muscle cells and adipocytes is still unknown.
Depletion of intracellular Ca2+ blocks insulin-stimulated
glucose uptake in 3T3-L1 adipocytes (Whitehead et al., 2001;
Worrall and Olefsky, 2002), suggesting that calcium-mobilizing
second messengers might be involved in linking the insulin
signaling pathways to GLUT4 translocation. Three functionally
distinct intracellular Ca2+-mobilizing systems triggered by
inositol-1,4,5-trisphosphate (IP3), cyclic ADP-ribose (cADPR),
and nicotinic acid-adenine dinucleotide phosphate (NAADP)
have been identified in previous studies (Berridge et al.,
2000). IP3 is generated by hydrolysis of phosphatidylinositol-4,
5-bisphosphate by a family of phospholipase C enzymes (Ber-
ridge et al., 2000). cADPR is generated by ADP-ribosyl cyclase
from nicotinamide dinucleotide (NAD) (Aarhus et al., 1995;
Howard et al., 1993). In mammalian cells, CD38 and BST-1
have suchADP-ribosyl cyclase activity (Aarhuset al., 1995;Hirataports 2, 1607–1619, December 27, 2012 ª2012 The Authors 1607
AB C
D E F
Figure 1. NAADP Mediates Insulin-Stimu-
lated Glucose Uptake in Adipocytes
(A) The effect of inhibitors of intracellular calcium
mobilization on insulin-stimulated glucose uptake
in 3T3-L1 adipocytes (left panel) and primary
adipocytes (right panel). Serum-starved 3T3-L1
and primary adipocytes were pretreated with
50 mM BAPTA-AM, 2 mM xestospongin C, 50 mM
8-bromo-cADPR (8-Br-cADPR), or 500 mM NED-
19 for 30 min. See also Figures S1 and S2.
(B) Insulin-stimulated NAADP production in 3T3-
L1 adipocytes.
(C) Insulin-stimulated glucose uptake in control or
CD38 siRNA-transfected 3T3-L1 adipocytes. After
transfection with control siRNA or CD38 siRNA,
CD38 expression levels (left panel) and glucose
uptake (right panel) were determined.
(D) Insulin-stimulated glucose uptake in wild-type
and CD38 KO primary adipocytes.
(E) The effect of NED-19 on insulin-stimulated
glucose uptake in CD38 KO adipocytes. CD38 KO
adipocytes were pretreated with 500 mM NED-19
for 30 min.
(F) Insulin-stimulated production of NAADP in
primary adipocytes isolated from wild and CD38
KO mice.
Glucose uptake or NAADP concentrations were
measured after stimulation of the cells with insulin
(100 nM for 30 min) in (A)–(F) as described in
Experimental Procedures. Data are expressed as
means ± SEM from three independent experi-
ments (*p < 0.01. **p < 0.05).et al., 1994). NAADP is generated by a base-exchange reaction
between NADP and nicotinic acid, which also is catalyzed by
ADP-ribosyl cyclases (Aarhus et al., 1995). CD38 is the only
ADP-ribosyl cyclase reported to possess the base-exchange
activity producing NAADP in mammals (Guse and Lee, 2008).
In this study, we demonstrate a function of NAADP as a central
mediator of GLUT4 and GLUT1 translocation, and glucose
uptake induced by insulin in adipocytes. In addition, we demon-
strate that PPARg sensitizes insulin activity by enhancing
NAADP production. PPARg-induced NAADP production is
mediated by transcriptional upregulation of CD38.1608 Cell Reports 2, 1607–1619, December 27, 2012 ª2012 The AuthorsRESULTS
Role of NAADP in Insulin-
Stimulated Glucose Uptake
in Adipocytes
We first determined which of the
known potential Ca2+ mobilizers can
contribute to insulin-stimulated glucose
uptake using 3T3-L1 and primary
adipocytes. Insulin stimulation (100 nM,
30 min) enhanced glucose uptake by
approximately 4-fold in 3T3-L1 adipo-
cytes compared to that in control cells
(Figure 1A, left panel). Chelation of intra-
cellular Ca2+ with 1,2-bis-(o-aminophe-
noxy)-ethane-N,N,N0,N0-tetraacetic acid
tetraacetoxymethyl ester (BAPTA-AM) abrogated the insulin-
stimulated glucose uptake in a good agreement with reports
by others (Whitehead et al., 2001; Worrall and Olefsky, 2002),
indicating that an increase of intracellular Ca2+ is required for
the proper insulin signaling leading to glucose uptake (Figure 1A).
Xestospongin C, an inhibitor of IP3, and 8-bromo cADPR, an
antagonist of cADPR, did not affect insulin-stimulated as well
as basal glucose uptake levels in 3T3-L1 adipocytes (Figure 1A,
left panel). In contrast, NED-19, which was recently identified as
an NAADP receptor antagonist (Naylor et al., 2009), completely
blocked insulin-stimulated glucose uptake at a dose of 500 mM
in 3T3-L1 and primary adipocytes (Figures 1A and S1). However,
NED-19 did not exert any effect on the classic insulin/PI3K/AKT
signaling pathway at 500 mM (Figure S2). Insulin also increased
intracellular NAADP by approximately 4-fold (Figure 1B). These
findings indicate that NAADP is a calcium mobilizer for insulin-
stimulated glucose uptake in adipocytes.
NAADP has been known to be synthesized by a base-
exchange reaction between NADP and nicotinic acid catalyzed
by ADP-ribosyl cyclases that are also involved in synthesis of
cADPR from NAD (Guse and Lee, 2008). In mammalian cells,
CD38 is the only enzyme possessing both ADP-ribosyl cyclase
activity and base-exchange activity (Guse and Lee, 2008).
CD38 knockdown with CD38 siRNA partially diminished
insulin-stimulated glucose uptake in 3T3-L1 adipocytes by
28% (Figure 1C). Similar results were seen in primary adipocytes
isolated from CD38 knockout (KO) mice and their littermate
controls (Figure 1D). NED-19 could block completely insulin-
stimulated glucose uptake in CD38 KO primary adipocytes
(Figure 1E). These suggest that insulin employs mostly a
CD38-independent NAADP synthetic pathway(s) to increase
NAADP, and stimulates glucose uptake in adipocytes. We
further confirmed the presence of CD38-independent produc-
tion by showing that NAADP concentration levels remained rela-
tively high in the CD38 KO primary adipocytes (76% of those of
wild-type primary adipocytes) in response to insulin (Figure 1F).
To characterize the CD38-independent synthetic pathway, we
measured ADP-ribosyl cyclase activity and base-exchange
activity in CD38 KO adipocytes. Neither ADP-ribosyl cyclase
activity nor base-exchange activity between nicotinic acid and
NAADP was detected in insulin-stimulated CD38 KO primary
adipocytes (data not shown), indicating no involvement of
ADP-ribosyl cyclase activity and base-exchange activity in
CD38-independent production of NAADP. Taken together,
insulin produces NAADP through two distinct CD38-dependent
and CD38-independent pathways. NAADP is essential for
insulin-stimulated glucose uptake, and its production is induced
by insulin mostly in a CD38-independent manner.
Role of NAADP in PPARg-Induced Glucose Uptake in
Adipocytes
We next examined whether NAADP mediates PPARg-induced
glucose uptake in adipocytes. Rosiglitazone, a PPARg agonist,
increased glucose uptake not only by itself but also additively
with insulin in 3T3-L1 adipocytes and primary adipocytes (Fig-
ure 2A). NED-19 blocked rosiglitazone-induced glucose uptake
in the absence or presence of insulin stimulation (Figure 2A), indi-
cating that NAADP mediates PPARg-induced as well as insulin-
stimulated glucose uptake in adipocytes. CD38 knockdown or
knockout completely abolished rosiglitazone-induced glucose
uptake in the absence of insulin stimulation, and it also
completely abolished rosiglitazone-induced enhancement of
glucose uptake in the presence of insulin stimulation (Figure 2B).
Rosiglitazone treatment increased NAADP concentrations in
control 3T3-L1 adipocytes and further enhanced them in
insulin-stimulated 3T3-L1 adipocytes (Figure 2C, upper). CD38
knockdown completely inhibited the rosiglitazone-induced
NAADP production in control 3T3-L1 adipocytes, and it also
completely inhibited rosiglitazone-induced enhancement ofCell ReNAADP production in insulin-stimulated 3T3-L1 adipocytes (Fig-
ure 2C, upper). These results indicate that rosiglitazone requires
CD38 to induce NAADP production and glucose uptake in 3T3-
L1 adipocytes. Rosiglitazone treatment also increased cADPR
concentrations in control 3T3-L1 adipocytes and further
enhanced cADPR levels in insulin-stimulated 3T3-L1 adipocytes
(Figure 2C, lower). CD38 knockdown markedly reduced cADPR
concentrations almost to basal levels not only under the basal
condition but also under rosiglitazone treatment (Figure 2C,
lower), indicating that CD38 is responsible for cADPR production
in 3T3-L1 adipocytes. Because rosiglitazone increased cADPR
as well as NAADP, we examined the contribution of cADPR on
rosiglitazone-induced glucose uptake. 8-Bromo-cADPR did
not affect rosiglitazone-induced enhancement of glucose uptake
(Figure 2D). These results indicate that the production of CD38-
mediated NAADP, but not cADPR, is involved in rosiglitazone-
induced glucose uptake. Taken together, these results demon-
strate that NAADP is involved in mediating both PPARg-induced
and insulin-stimulated glucose uptake. PPARg-induced NAADP
production requires CD38, whereas insulin-stimulated NAADP
production requires an additional pathway besides CD38.
Transcriptional Upregulation of CD38 by PPARg
Since it became clear to us that CD38 was required for PPARg-
induced glucose uptake, we hypothesized that CD38 might be
a target gene for PPARg. Indeed, rosiglitazone increased
expression of CD38 at the mRNA as well as protein levels in
a dose-dependent manner (Figure 3A). In addition, PPARg
knockdown with PPARg siRNA inhibited CD38 expression in ro-
siglitazone-treated 3T3-L1 adipocytes (Figure 3B). To determine
whether the CD38 gene is a transcriptional target for PPARg, we
attempted to search for the PPAR responsive element (PPRE)
consensus sequences, a direct repeat of AGGTCA spaced by
one nucleotide (Berger et al., 1996; Kliewer et al., 1992), in the
CD38 promoter region, but were unable to find any consensus
sequences matching the PPRE in an upstream region up to 3
kb from the CD38 gene. However, a PPRE-like motif, AGGTCA
CAGGCGA, was observed in the intron 1 region spanning
from +705 to +717 (Figure 3C). To evaluate the putative PPRE,
we constructed a luciferase reporter gene plasmid in which
a 1.9 kb upstream (1,898/+3 from the transcription start site)
was inserted into the promoter region of the luciferase reporter
gene (pGL3-1.9-Luc) (Figure 3D). The plasmid was modified by
inserting 0.5 kb intron 1 DNA (+231/+719 from the transcription
start site, 41/+448 from the intron 1 start site) containing the
putative PPRE into the downstream of the pGL3-1.9-Luc desig-
nated as pGL3-1.9-Luc-0.5. To examine specific effect of the
putative PPRE, we also constructed a plasmid (pGL3-1.9-Luc-
0.5D) (+231/+684 from the transcription start site) in which the
putative PPRE was deleted from pGL3-1.9-Luc-0.5.
pGL3-1.9-Luc showed transcriptional activity at only amodest
level under ectopic expression of PPARg, confirming that the 1.9
kb promoter region does not contain a PPRE responsive to
PPARg in 3T3-L1 adipocytes (Figure 3D). However, transcrip-
tional activity of pGL3-1.9-Luc-0.5 showed a 2-fold stronger
transcriptional activity than pGL3-1.9-Luc (Figure 3D).Moreover,
an additional 2-fold increase in the transcriptional activity of
pGL3-1.9-Luc-0.5 was detected by ectopic expression ofports 2, 1607–1619, December 27, 2012 ª2012 The Authors 1609
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Figure 2. NAADP Mediates PPARg-Induced
Glucose Uptake in Adipocytes
(A) The effect of NED-19 on PPARg-induced
glucose uptake in 3T3-L1 adipocytes (left panel)
and primary adipocytes (right panel). 3T3-L1
adipocytes and primary adipocytes were cultured
for 48 hr in the presence of 1 mM rosiglitazone. The
cells were pretreated with 500 mM NED-19 for
30 min.
(B) The effect of CD38 knockdown (left panel) or
CD38 gene knockout (right panel) on PPARg-
induced glucose uptake. 3T3-L1 adipocytes
transfected with control or CD38 siRNA, and wild
or CD38 KO primary adipocytes were cultured for
48 hr in the presence of 1 mM rosiglitazone.
(C) The effect of CD38 knockdown on insulin and/
or rosiglitazone-induced increase in NAADP
(upper) and cADPR (lower) concentration in 3T3-
L1 adipocytes. 3T3-L1 adipocytes were trans-
fected with control or CD38 siRNA. The cells were
plated on a 100 mm culture dish and cultured for
48 hr in the presence of 1 mM rosiglitazone.
(D) The effect of 8-bromo cADPR (8-Br-cADPR) on
PPARg-induced glucose uptake in 3T3-L1 adipo-
cytes. 3T3-L1 adipocytes were cultured with 1 mM
rosiglitazone for 48 hr and pretreated with 50 mM
8-bromo cADPR for 30 min.
For (A)–(D), glucose uptake or cADPR and NAADP
concentrations weremeasured after the cells were
stimulated with insulin (100 nM for 30 min). Data
are expressed as means ± SEM from three inde-
pendent experiments (*p < 0.05).PPARg, suggesting that the intron 1 contributes to its respon-
siveness to PPARg (Figure 3D). In addition, rosiglitazone treat-
ment even further promoted the transcriptional activity of
pGL3-1.9-Luc-0.5 (Figure 3D). In contrast, pGL3-1.9-Luc-0.5D
showed no or little responsiveness to PPARg (Figure 3D), indi-
cating that the putative PPRE located in the region from +685
to +719 may act as a functional transcriptional promoter. Next,
we determined whether PPARg can actually bind to the putative
PPRE using electrophoretic mobility shift assays (EMSA) with an
oligonucleotide probe containing the putative PPRE sequences
(+697 to +726 bp). The EMSA indicated that a small fraction of
the probe was shifted by the nuclear extracts from 3T3-L1 cells
and its shift was amplified by ectopic expression of PPARg1610 Cell Reports 2, 1607–1619, December 27, 2012 ª2012 The Authors(Figure 3E). The shift of the probe was
abolished by the presence of excessive
unlabeled probe, indicating that the puta-
tive PPRE had a specific binding affinity
to PPARg. We then performed a chro-
matin immunoprecipitation (ChIP) assay
in 3T3-L1 adipocytes to test the recruit-
ment of PPARg to the PPRE in the intron
1. DNA/protein complexes were immuno-
precipitated with anti-PPARg antibody
and then the purified DNA was amplified
with primers flanking the PPRE (+633
to +743). As shown in Figure 3F, rosiglita-
zone treatment induced PPARg recruit-ment to the PPRE in 3T3-L1 adipocytes. Taken together, these
results demonstrated that CD38 is a target gene for PPARg,
and thus PPARg induces CD38 upregulation and subsequently
enhances glucose uptake by NAADP production.
Insulin-Stimulated and PPARg Agonist-Induced Glucose
Uptake via NAADP-Mediated Calcium Signaling
Because NAADP is involved in intracellular Ca2+ mobilization
from the endolysosomal system (Brailoiu et al., 2009), we
examined whether NAADP-mediated Ca2+ mobilization was
integral in the processes of insulin-stimulated glucose uptake.
In fact, insulin induced an increase in intracellular calcium con-
centration ([Ca2+]i) in 3T3-L1 adipocytes and, more importantly,
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Figure 3. Identification of PPRE in the First
Intron of Mouse CD38 Gene
(A) CD38 expression induced by rosiglitazone.
3T3-L1 adipocytes were cultured with the indi-
cated concentrations of rosiglitazone for 48 hr.
CD38 expression levels were determined by
western blot (upper panel) and RT-PCR (lower
panel). b-Actin and 18 s RNA were used to eval-
uate equal protein or mRNA loading.
(B) The effect of PPARg knockdown on rosiglita-
zone-induced expression of CD38. 3T3-L1
adipocytes were transfected with control or
PPARg siRNA, and cultured with 1 mM rosiglita-
zone for 48 hr. CD38 and PPARg expression levels
were determined by western blot.
(C) DNA sequence (from 1 to +1,150) covering
exon 1 and part of intron 1 of the mouse CD38
gene. Nucleotide numbering begins at the tran-
scription start site (designated +1). The putative
PPRE motif is boxed.
(D) The validation of the PPRE motif in intron 1
of the mouse CD38 gene. Structure of the
mouse CD38 gene is schematically shown
(upper). Luciferase reporter plasmids containing
the 1.9 kbp CD38 promoter alone (pGL-1.9-Luc),
the promoter plus 0.5 kbp intron 1 (pGL-1.9-
Luc-0.5), and the promoter plus PPRE-deleted
0.5 kbp intron 1 (pGL-1.9-Luc-0.5D) were con-
structed and illustrated (middle). After 3T3-L1
adipocytes were cotransfected with the plas-
mids containing pcDNA or the PPARg expres-
sion vector pcDNA-flag-PPARg (PPARg) and
cultured for 48 hr in the presence or absence
of 1 mM rosiglitazone, luciferase activity was
assayed (lower). Data are expressed as means ±
SEM from three independent experiments
(*p < 0.05).
(E) EMSA showing binding of PPARg to the
PPRE in +697/+726 region of intron 1 of the
mouse CD38 gene. 3T3-L1 fibroblasts were
transfected with pcDNA or pcDNA-flag-PPARg
(PPARg) and cultured for 48 hr. PPARg expres-
sion levels (left panel) in nuclear fractions were
determined by western blot. EMSA (right panel)
was performed with 32P-labeled oligonucleotides
(+697/+726 region of the mouse CD38 gene).
Unlabeled oligonucleotides at 30-fold molar ex-
cess to the labeled probe were used to perform
competition assays.
(F) ChIP assay demonstrating binding of PPARg to the PPRE in the intron 1 of the mouse CD38 gene. Crosslinked chromatin from 3T3-L1 adipocytes cultured
for 48 hr with or without 1 mM rosiglitazone was incubated with PPARg antibodies or normal rabbit immunoglobulin G as a control. Immunoprecipitates were
analyzed by PCR using primers specific for the intron 1 region containing the PPRE of the mouse CD38 gene. The input included in the PCR was conducted with
2% of the total chromatin.the insulin-induced [Ca2+]i increase was blocked by NED-19
(Figure 4A). We also found that insulin-induced [Ca2+]i increase
was even further enhanced by rosiglitazone treatment (Fig-
ure 4A). Rosiglitazone treatment also increased the basal levels
of [Ca2+]i. These increases of [Ca
2+]i induced by insulin and
a combination of insulin and rosiglitazone were completely
blocked by NED-19 (Figure 4A). Bafilomycin A1, an inhibitor of
the lysosomal H(+)-ATPase, blocked insulin-stimulated and
rosiglitazone-enhanced increase of [Ca2+]i (Figure 4A), indicating
involvement of the endolysosomal system in NAADP-mediated
Ca2+ signaling in adipocytes. Bafilomycin A1 also blockedCell Reinsulin-stimulated and rosiglitazone-induced glucose uptake
(Figure 4B).
To determine the effect of NAADP-induced [Ca2+]i increase on
glucose uptake, we used NAADP-AM, a derivative of NAADP,
because it can permeate the cell membrane (Parkesh et al.,
2008). NAADP-AM significantly increased glucose uptake in
a dose-dependent manner, reaching a maximum level at a
dose of 50 nM (Figure 4C). Consistent with these results,
NAADP-AM increased [Ca2+]i accordingly (Figure 4D). NAADP-
AM-induced increases of glucose uptake and [Ca2+]i in 3T3-L1
adipocytes were completely blocked by NED-19 at 500 mMports 2, 1607–1619, December 27, 2012 ª2012 The Authors 1611
NAADP-AM (nM)
NED-19 (500 μM)
_
_ _ _ _ _ +
1 10 25 50 50100_
Control NED -19 (20 min)
500_
B
A
D
C
0
500
1000
1500
2000
2500
3000
3500
4000
4500
G
lu
co
se
 u
pt
ak
e
(p
m
ol
e/
m
in
/m
g)
 Vehicle
 Bafilomycin A1
Insulin
Rosiglitazone
_
_
_
+
+
+_
+
0 100 200 300 400 500 600
0
100
200
300
400
500
n=6
Vehicle
[C
a2
+ ] i,
 n
M
Time (s)
0 100 200 300 400 500 600
0
100
200
300
400
500
n=5Insulin
[C
a2
+ ] i,
 n
M
Time (s)
0 100 200 300 400 500 600
0
100
200
300
400
500
n=6
Insulin
[C
a2
+ ] i,
 n
M
Time (s)
0 100 200 300 400 500 600
0
100
200
300
400
500
n=6
Insulin
[C
a2
+ ] i,
 n
M
Time (s)
0 100 200 300 400 500 600
0
100
200
300
400
500
n=5
Insulin
[C
a2
+ ] i,
 n
M
Time (s)
0 100 200 300 400 500 600
0
100
200
300
400
500
n=5
Insulin
[C
a2
+ ] i,
 n
M
Time (s)
0 100 200 300 400 500 600
0
100
200
300
400
500
n=5
Insulin
[C
a2
+ ] i,
 n
M
Time (s)
0
200
400
600
800
1000
 G
lu
co
se
 u
pt
ak
e
(p
m
ol
e/
m
in
/m
g)
0 100 200 300 400 500 600
0
100
200
300
400
500
n=5
NAADP-AM
[C
a2
+ ] i,
 n
M
Time (s)
0 100 200 300 400 500 600
0
100
200
300
400
500
n=5
NAADP-AM
[C
a2
+ ] i,
 n
M
Time (s)
Insulin __Rosiglitazone
NED-19 (500 μM)
Bafilomycin
NAADP-AM
_
_
+ +
+
+
+_
_ _
_
_ _ _
+
+
+_
+_
_
+
+
+_
_
+
+
+
0
100
200
300
400
[C
a2
+ ] i 
(n
M
) a
t 5
00
 s
NED-19 (500 μM)
0
100
200
300
400
[C
a2
+ ] i 
(n
M
) a
t 5
00
 s
+
Control Control Rosiglitazone (48 h)
NED-19 (20min) Rosiglitazone (48 h)NED-19 (20min) Bafilomycin A1 (20 min)
Rosiglitazone (48 h)
Bafilomycin A1 (20 min)
(legend continued on next page)
1612 Cell Reports 2, 1607–1619, December 27, 2012 ª2012 The Authors
(Figures 4C and 4D). We confirmed the cell permeability of
NAADP-AM by the finding that treatment of 3T3-L1 adipocytes
with 50 nM NAADP-AM increased intracellular NAADP concen-
trations by 2-fold from control levels (Figure S3). These results
indicate that the NAADP-mediated Ca2+signaling pathway is
critical for both insulin-stimulated and PPARg agonist-induced
glucose uptake in adipocytes.
GLUT4 and GLUT1 Translocation by NAADP-Mediated
Calcium Signaling
Rosiglitazone induces GLUT4 and GLUT1 translocation in 3T3-
L1 adipocytes (Standaert et al., 2002). Both GLUT4 and GLUT1
translocation contribute to insulin-stimulated glucose uptake in
3T3-L1 adipocytes (Liao et al., 2006). It is known that depletion
of [Ca2+]i blocks insulin-stimulated glucose uptake (Whitehead
et al., 2001; Worrall and Olefsky, 2002). These findings suggest
that GLUT4 and GLUT1 translocation may be an important
mediator of insulin-stimulated and PPARg activation-induced
glucose uptake. Thus, we determined the interrelationship
between intracellular NAADP and [Ca2+]i with GLUT4 and
GLUT1 translocation. Insulin promoted translocation of both
GLUT4 and GLUT1 to the plasma membrane, and the insulin-
promoted GLUT4 and GLUT1 translocation was further
increased by rosiglitazone (Figures 5A and 5B). NED-19 abol-
ished the effects of both insulin-stimulated and rosiglitazone-
induced GLUT4 and GLUT1 translocation (Figures 5A and 5B).
Likewise, NAADP-AM increased GLUT4 and GLUT1 transloca-
tion, and this effect was also blocked by NED19 (Figures 5C
and 5D). CD38 knockdown partially inhibited insulin-stimulated
GLUT4 and GLUT1 translocation (Figure 5E), consistent with
glucose uptake data (Figure 1C). These results suggest that
both GLUT4 and GLUT1 are common targets for NAADP-medi-
ated Ca2+ signaling to facilitate glucose uptake in response to
insulin stimulation and PPARg activation.
Osmotic shock can stimulate GLUT4 translocation by [Ca2+]i,
but not by the insulin signaling pathway (Chen et al., 1997; Wor-
rall and Olefsky, 2002); however, we did not detect any effect of
NED-19 on osmotic shock-induced GLUT4 translocation (Fig-
ure 5F), indicating that osmotic shock-induced GLUT4 translo-
cation is mediated by [Ca2+]i generated from sources other
than the NAADP-sensitive Ca2+ pool. These data indicate that
the NAADP/Ca2+ signaling pathway plays a unique role in
GLUT4 and GLUT1 translocation induced by insulin stimulation
and PPARg activation.Figure 4. NAADP Mediates Insulin-Stimulated and PPARg-Induced Glu
(A) The effect of NED-19 and bafilomycin A1 on insulin-stimulated and PPARg-in
with or without 1 mM rosiglitazone for 48 hr. The cells dissociated with Accutase we
30 min. After the cells were treated with 500 mM NED-19 or 1 mM bafilomycin A1 f
(B) The effect of bafilomycin A1 on insulin-stimulated and PPARg-induced glucose
presence of 1 mM rosiglitazone. Glucose uptake was measured after the cells we
(C) The effect of NAADP-AMon glucose uptake. After treatment of 3T3-L1 adipocy
was determined. Data are expressed as means ± SEM from three independent e
(D) The effect of NAADP-AM on [Ca2+]i. 50 nM NAADP-AM was added to Fura
for 30 min.
For (A) and (D), recordings of [Ca2+]i changes were obtained from five or six singl
Graph bars represent means ± SEM of [Ca2+]i at 500 s from the start (n = 5–6). Th
results. See also Figure S3.
Cell ReInsulin-Stimulated NAADP Are Mediated by the
IR/IRS-1/PI3K/AKT Signaling Pathway
The IR/IR substrate-1 (IRS-1)/phosphoinositide 3-Kinase (PI3K)/
AKT signaling pathway is involved in GLUT4 and GLUT1 translo-
cation and glucose uptake induced by insulin (Cheatham et al.,
1994; Clarke et al., 1994). The cyclic GMP pathway is known
to activate CD38’s ability to produce cADPR and NAADP (Rah
et al., 2005). To determine whether there is a relationship
between the NAADP pathway and the IR/IRS-1/PI3K/AKT
pathway, we examined the effect of HNMPA, an IRS-1 blocker,
wortmannin and LY294002, PI3K inhibitors, and (Rp)-8-pCPT-
cGMP-S, a protein kinase G (PKG) inhibitor, on insulin-induced
NAADP production. Insulin stimulated AKT phosphorylation
that was blocked by HNMPA, wortmannin, and LY294002, but
not (Rp)-8-pCPT-cGMP-S (Figure 6A). Insulin also increased
the phosphorylation levels of vasodilator-stimulated phospho-
protein (VASP, the major PKG phosphorylation site), which was
blocked by (Rp)-8-pCPT-cGMP-S, but not HNMPA and wort-
mannin (Figure 6B). These results indicate that insulin activates
two distinct PKG and IR/IRS-1/PI3K/AKT pathways. HNMPA,
wortmannin, and LY294002 completely inhibited insulin-
stimulated NAADP production, but (Rp)-8-pCPT-cGMP-S
partially inhibited it (Figure 6C). These findings indicate that
insulin-stimulated NAADP production is dependent on the IR/
IRS-1/PI3K/AKT pathway. It is possible that the partial inhibition
of insulin-stimulated NAADP production by (Rp)-8-pCPT-
cGMP-S was due to inhibition of the CD38-dependent pathway
by (Rp)-8-pCPT-cGMP-S but not the CD38-independent
pathway, because CD38 plays a relatively small role in insulin-
stimulated NAADP production in adipocytes (24% inhibition by
CD38 knockout, see Figure 1F). To confirm this, we overex-
pressed CD38 by CD38 gene transfection to amplify the CD38
signaling pathway, and examined the effect of HNMPA, wort-
mannin, LY294002, and (Rp)-8-pCPT-cGMP-S on insulin-
induced NAADP production. CD38 overexpression increased
insulin-stimulated NAADP synthesis by approximately 30% (Fig-
ure 6C), indicating that insulin activates CD38-dependent as well
as CD38-independent NAADP production. The inhibition of IR/
IRS-1/PI3K/AKT blocked insulin-stimulated NAADP production
and abolished the enhancement of insulin-stimulated NAADP
production by CD38 overexpression (Figure 6C), indicating that
insulin-stimulated NAADP production by CD38 requires the acti-
vation of IR/IRS-1/PI3K/AKT pathway. (Rp)-8-pCPT-cGMP-S
partially inhibited insulin-stimulated NAADP production andcose Uptake by [Ca2+]i Increase
duced [Ca2+]i increase in 3T3-L1 adipocytes. 3T3-L1 adipocytes were cultured
re cultured onMatrigel-coated coverslips and loadedwith 10 mMFura 2-AM for
or 30 min, 100 nM insulin was added to Fura 2-AM-loaded 3T3-L1 adipocytes.
uptake in 3T3-L1 adipocytes. 3T3-L1 adipocytes were cultured for 48 hr in the
re stimulated with insulin (100 nM for 30 min).
tes with the indicated concentrations of NAADP-AM for 30min, glucose uptake
xperiments.
2-AM-loaded 3T3-L1 adipocytes pretreated with or without 500 mM NED-19
e 3T3-L1 adipocytes as described. Each line represents [Ca2+]i in a single cell.
ese are representatives of three independent experiments that showed similar
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Figure 5. Insulin and Rosiglitazone Induce GLUT4 and GLUT1 Translocation by Activation of the NAADP Signaling Pathway
(A) The effect of NED-19 on insulin-stimulated and PPARg activation-induced GLUT4 translocation.
(B) The effect of NED-19 on insulin-stimulated and PPARg activation-induced GLUT1 translocation.
(C) The effect of NAADP-AM on GLUT4 translocation.
(D) The effect of NAADP-AM on GLUT1 translocation.
(E) The effect of CD38 knockdown on insulin-stimulated GLUT4 and GLUT1 translocation. 3T3-L1 adipocytes transfected with control or CD38 siRNA were
stimulated with 100 nM insulin for 30 min.
(F) The effect of NED-19 on osmotic shock-induced GLUT4 translocation. 3T3-L1 adipocytes were treated with 600mM sorbitol to induce osmotic shock at 37C
for 20 min with or without 500 mM NED-19.
(legend continued on next page)
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Figure 6. The Effect of IR/IRS-1/PI3K/AKT
and PKG Pathways on Insulin-Stimulated
NAADP Production
(A) The effect of HNMPA, wortmannin, LY294002,
and (Rp)-8-pCPT-cGMP-S on insulin-stimulated
AKT phosphorylation.
(B) The effect of HNMPA, wortmannin, and (Rp)-8-
pCPT-cGMP-S on insulin-stimulated VASP phos-
phorylation at ser239.
(C) The effect of HNMPA, wortmannin, LY294002,
and (Rp)-8-pCPT-cGMP-S on insulin-stimulated
NAADP production in control or CD38-overex-
pressed 3T3-L1 adipocytes. After transfection of
3T3-L1 adipocytes with pcDNA or pcDNA-CD38,
the cells were further treated with 100 mMHNMPA,
100 nM wortmannin, 100 mM LY294001, or 20 mM
(Rp)-8-pCPT-cGMP-S for 30 min. After insulin
stimulation (100 nM, 30 min), CD38 expression
levels (left panel) and intracellular NAADP
concentrations (right panel) were measured. Data
are expressed as means ± SEM from three inde-
pendent experiments (*p < 0.05).
For (A) AND (B), 3T3-L1 adipocytes were pre-
treated with 100 mM HNMPA, 100 nM wortman-
nin, 100 mM LY294002, or 20 mM (Rp)-8-pCPT-
cGMP-S for 30 min. After insulin stimulation
(100 nM, 30 min), phospho-AKT Ser473, AKT,
phosphor-VASP Ser239, and b-actin were de-
tected in the cell lysates by western blotting.abolished the enhancement of insulin-stimulated NAADP
synthesis by CD38 overexpression (Figure 6C), indicating that
insulin-stimulated NAADP production by CD38 requires the acti-
vation of the PKG pathway. These data suggest that CD38-
dependent NAADP production by insulin requires simultaneous
inputs from two separate PKG and IR/IRS-1/PI3K/AKT signaling
pathways. The inhibition of PKG and IRS-1/PI3K/AKT signaling
pathways had no effect on rosiglitazone-induced NAADP
production in control 3T3-L1 adipocytes (data not shown), sug-
gesting that CD38, which is induced by rosiglitazone, may
increase basal NAADP concentrations by constitutive synthesis.
Taken together, these results demonstrate that CD38-depen-
dent and CD38-independent NAADP synthesis are differently
regulated.
CD38 Knockout Inhibits PPARg-Induced Amelioration
of Glucose Tolerance in Diabetic Mice
Because rosiglitazone was shown to be a strong inducer of
NAADP production, we next determined whether rosiglitazone
could sensitize insulin responses and, if so, whether or not the
rosiglitazone effect on sensitizing insulin responses requires
CD38-mediated NAADP production. The administration of nico-For (A) and (B), 3T3-L1 adipocytes were cultured with 1 mM rosiglitazone for 48 hr a
for 30min. For (C) and (D), 3T3-L1 adipocytes were treated with 50 nMNAADP-AM
membrane fractions (PM) and total cell lysates (Total) were determined bywestern
by the quantification of protein band intensities from triplicate experiments (lowe
(A)–(F) (*p < 0.01; **p < 0.05).
Cell Retinamide and streptozotocin creates an experimental diabetic
syndrome closer to type 2 diabetes, unlike a single injection
of streptozotocin (Masiello et al., 1998). Thus, we compared
10- to 12-week-old wild-type and CD38 KO mice in regard to
the degrees of glucose tolerance after inducing insulin resistance
with administration of nicotinamide (1,000mg/kg) and streptozo-
tocin (150 mg/kg). Wild-type and CD38 KO mice had a similar
response to the administration of nicotinamide and streptozoto-
cin, with both showing lower glucose tolerance (Figures 7A and
7B) and an approximately 50% decrease in insulin secretion
compared to untreated mice (Figure 7C). However, there was
a significant difference in glucose tolerance between diabetic
wild-type and diabetic CD38 KO mice after two consecutive
administrations of rosiglitazone at a 12 hr interval. Diabetic
wild-type mice, but not diabetic CD38 KOmice, had significantly
improved glucose tolerance as a result of rosiglitazone adminis-
tration (Figures 7A and 7B). Rosiglitazone increased NAADP
production and GLUT4 translocation in response to glucose
administration in diabetic wild-type, but not diabetic CD38 KO,
mice (Figures 7D and 7E). These results strongly support our
hypothesis that CD38 is involved in the PPARg-induced insulin
sensitization via an NAADP signaling pathway.nd stimulated with 100 nM insulin in the presence of vehicle or 500 mMNED-19
for 30minwith or without 500 mMNED-19. GLUT4 andGLUT1 levels in plasma
blotting (upper). Ratios of total to membrane GLUT4 or GLUT1were calculated
r). Data are expressed as means ± SEM from three independent experiments
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Figure 7. CD38 Knockout Inhibits Rosiglitazone-Induced Amelioration of Glucose Tolerance in Diabetic Mice
(A) Glucose tolerance test in rosiglitazone-treated in diabetic wild-type and CD38 KOmice. Data are expressed as means ± SEM; n = 7 per each group (*p < 0.05
compared to nondiabetic; #p < 0.05 compared to diabetic + vehicle; p^ < 0.05 for nondiabetic versus diabetic vehicle; ^^p < 0.05 for nondiabetic versus diabetic +
rosiglitazone).
(B) The effect of rosiglitazone on the area under the blood glucose concentration during glucose tolerance test in diabetic wild-type and CD38 KOmice. Data are
expressed as means ± SEM; n = 7 per each group (*p < 0.05).
(C) The effect of rosiglitazone on insulin levels during glucose tolerance test in diabetic wild-type and CD38 KOmice. Plasma insulin levels in wild-type and CD38
KO mice were 0.24 ± 0.01 and 0.22 ± 0.03, respectively. Data are expressed as means ± SEM; n = 7 per each group (*p < 0.01).
(legend continued on next page)
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DISCUSSION
Insulin stimulates glucose uptake in muscle and adipose tissues
by promoting the translocation of GLUT4 from intracellular
storage sites to the cell surface (Hausdorff et al., 1995; Olson
et al., 1997). The signaling pathway that links insulin signaling
to GLUT4 translocation remains poorly understood. The mecha-
nism of action of PPARg agonist, which increases the sensitivity
of glucose transport to insulin, is also unclear. In this study, we
determined the link between insulin signaling and GLUT4 and
GLUT1 translocation in adipocytes. We found that insulin acti-
vates the IR/IRS-1/PI3K/AKT and PKG signaling pathways, and
induces NAADP production via CD38-dependent and CD38-
independent pathways. NAADP increases [Ca2+]i, which results
in GLUT4 and GLUT1 translocation to the plasma membrane,
thereby allowing glucose uptake. PPARg agonist also contrib-
utes to increase glucose uptake by upregulation of CD38, which
enhances intracellular NAADP concentration and insulin-stimu-
lated glucose uptake. Insulin-stimulated NAADP production by
the CD38-dependent pathway requires the activation of both
PKG and IR/IRS-1/PI3K/AKT signaling pathways. Insulin-stimu-
lated NAADP production by the CD38-independent pathway
requires activation of the IR/IRS-1/PI3K/AKT pathway. These
results explain how PPARg agonist enhances insulin responses
through CD38 in adipocytes.
Studies by others have demonstrated that NAADP plays
important roles in pancreatic b cells. NAADP mediates insulin
secretion by pancreatic b cells through Ca2+ signaling in
response to glucose and glucagon-like peptide-1 (Kim et al.,
2008; Masgrau et al., 2003). Autocrine activation of IRs in
pancreatic b cells may be linked to NAADP signaling pathways
(Shawl et al., 2009). It has been reported that NAADP-sensitive
calcium stores initiate insulin signaling in human pancreatic
b cells (Johnson and Misler, 2002). Our studies provide addi-
tional information on the role of NAADP in insulin-stimulated
glucose uptake and PPARg-induced insulin sensitization in
adipocytes.
Engagement of intracellular calcium in insulin responses,
including GLUT4 translocation, in adipocytes is well docu-
mented. Calmodulin antagonists inhibit insulin-stimulated
glucose transport, and depletion of intracellular calcium blocks
insulin-stimulated GLUT4 translocation in 3T3-L1 adipocytes
(Worrall and Olefsky, 2002; Yang et al., 2000). Furthermore, in
rat primary adipocytes, magnitude of insulin-stimulated glucose
uptake is correlated with intracellular free Ca2+ concentration
ranging from 140 to 370 nM (Draznin et al., 1987). So far, the
key messengers that mediate calcium mobilization in response
to insulin have not been identified. We demonstrate that NAADP
is a specific calciummobilizer involved in insulin signal transduc-
tion necessary for GLUT4 and GLUT1 translocation. We also(D) The effect of rosiglitazone on oral glucose load-stimulated NAADP production
from three sets of replicated experiments (*p < 0.05.)
(E) The effect of rosiglitazone on oral glucose load-stimulated GLUT4 translocation
from three sets of replicated experiments (*p < 0.05).
Nicotinamide (1,000mg/kg) and streptozotocin (150mg/kg) were intraperitoneally
orally administered twice at an interval of 12 hr and then glucose tolerance testwas
glucose tolerance test (C). NAADP levels (D) and GLUT4 translocation (E) were de
Cell Rerevealed the mechanism by which PPARg agonist sensitizes
insulin responses by showing that PPARg agonist produces
NAADP and cADPR by CD38 upregulation and consequently
increases [Ca2+]i. In contrast to NAADP, cADPR does not seem
to be involved in intracellular calcium mobilization in adipocytes.
It appears that NAADP is synthesized in vivo via two distinct
pathways: the CD38-dependent or CD38-independent route.
Cosker et al. showed that CD38 is required for endogenous
NAADP generation in response to cholecystokinin stimulation
in pancreatic acinar cells (Cosker et al., 2010). Rah et al. also
demonstrated that CD38 is responsible for NAADP generation
for Ca2+ signaling in lymphokine-activated killer cells (Rah
et al., 2010). However, Soares et al. demonstrated that human
myometrial cells utilize a CD38-independent pathway to
generate NAADP and induce intracellular Ca2+ transients in
response to histamine (Soares et al., 2007). In the present study,
we demonstrated that insulin produced NAADP by both CD38-
dependent and CD38-independent pathways. CD38 knockout
partially blocked insulin-stimulated NAADP production (Fig-
ure 1F). CD38 knockdown decreased insulin stimulated-NAADP
production, while CD38 overexpression increased insulin-
stimulated NAADP production in adipocytes (Figures 2C and
6C). These results indicate that CD38 partially contributes to
insulin-stimulated NAADP production. In addition, our results
showed that CD38 upregulation by PPARg activation resulted
in an increase of NAADP and intracellular calcium in 3T3-L1
adipocytes (Figures 2C and 4A). These findings suggest that
the CD38-dependent pathway is responsible for in vivo genera-
tion of NAADP in response to some physiological stimuli, such as
insulin, PPARg agonist, interleukin, and cholecystokinin, and the
CD38-independent pathway induces NAADP production by
insulin and histamine.
Improving insulin sensitivity is an urgent remedy for the treat-
ment of type 2 diabetes mellitus. Although PPARg agonists have
been developed and used for the treatment of this disease, their
underlying mechanisms remain largely unknown. This report
demonstrates that NAADP is a key central second messenger
for PPARg agonists to enhance insulin sensitivity. The enzymes
responsible for the synthesis of NAADP are potential therapeutic
targets to revert the symptomatic insulin insensitivity of type 2
diabetes mellitus.
EXPERIMENTAL PROCEDURES
Development of 3T3-L1 Adipocytes and Isolation of Primary
Adipocytes
3T3-L1 adipocytes were prepared by treating 3T3-L1 cells (American Type
Culture Collection, Manassas, VA, USA) with a hormone cocktail solution
(1 mM dexamethasone, 10 mg/ml insulin, 500 mM isobutylmethylxanthine) in
10% fetal calf serum (FCS) for 2 days and the medium was replaced with
Dulbecco’s modified Eagle’s medium (DMEM) supplemented with 10% FCSin the adipose tissues of diabetic wild-type and CD38 KO mice. The data were
in the adipose tissues of diabetic wild-type and CD38 KOmice. The data were
injected to create diabetic mice. Twoweeks later, rosiglitazone (10mg/kg) was
performed (A andB). Plasma insulin levelswere determined at 10minduring the
termined 45 min after oral glucose treatment during the glucose tolerance test.
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and 10 mg/ml insulin every other day for an additional 7–10 days. Primary
adipocytes were prepared by treating the epididymal fat pads from wild and
CD38/ mice for 1 hr with KRH buffer (118 mM NaCl, 4.7 mM KCl, 1.2 mM
MgSO4, 2.5 mM CaCl2, 1.2 mM KH2PO4, 25 mM HEPES, 1 mM EDTA, and
2 mM glucose) containing 2% BSA, 200 nM adenosine, and 1 mg/ml collage-
nase II and filtered through a 250 mm nylon mesh to remove tissue debris. The
isolated primary adipocytes were attached to Matrigel-coated coverslips as
described elsewhere (Hazen et al., 1995).
RT-PCR
RNA extraction and RT-PCR were carried out according to the standard
procedures described in detail in Extended Experimental Procedures.
Determination of Intracellular NAADP and cADPR Concentration
Intracellular NAADP and cADPR concentration was determined as described
previously (Gasser et al., 2006; Graeff and Lee, 2002).
Assay for CD38 Promoter Activity
A 1.9-kb promoter fragment and two intron fragments of different sizes for
the mouse CD38 gene were generated by PCR from mouse genomic DNA
and cloned into the pGL3-Basic vector (Promega, Madison, WI, USA). The
luciferase reporter vectors were electroporated into 3T3-L1 adipocytes using
Amaxa solution L kit (Amaxa, Cologne, Germany). The dual luciferase kit
(Promega) was used for detection of luciferase activity. (See also Extended
Experimental Procedures.)
EMSA
EMSA was carried out according to standard procedures, as described in
Extended Experimental Procedures.
ChIP analysis
ChIP analysis was performed as described in ChIP assay kit (Upstate Biotech-
nology, Lake Placid, NY, USA). A rabbit anti-PPARg antibody and a normal
rabbit immunoglobulin G (5 mg per sample; Santa Cruz Biotechnology, Santa
Cruz, CA, USA) were used for immunoprecipitation. The purified DNA was
used for PCR analysis. See Extended Experimental Procedures for a list of
primers used.
[3H]-2-Deoxy-D-glucose Uptake Assay
3T3-L1 adipocytes or primary adipocytes (1 3 105 cells/well) were serum-
starved for 4 hr in 24-well plates and rinsed with KRPH buffer solution (5 mM
phosphate [pH 7.4], 20 mM HEPES [pH 7.4], 1 mM MgSO4, 1 mM CaCl2,
136 mM NaCl, 4.7 mM KCl). The cells were incubated with [3H]-2-deoxy-D-
glucose (NEN Life Science Products, Boston, MA, USA) at 1 mCi/well for
10 min at room temperature in 500 ml KRPH buffer solution supplemented
with 100 mM2-deoxy-D-glucose. Glucose uptake was stopped by the addition
of cold PBS containing 50 mMcytochalasin on ice. After washing with cold PBS
four times, the cells were lysed in 0.5 ml of 0.1 NNaOH per well and neutralized
with 40 ml of 1 N HCl. The cell lysates were mixed with 4 ml of Ecoscint A scin-
tillation fluid (National Diagnostics, Atlanta, GA, USA) and radioactivity was
measured with a liquid scintillation counter.
Overexpression of CD38 and Knockdown of CD38 or PPARg
For overexpression of CD38, 3T3-L1 adipocytes were transfected with 5 mg of
pcDNA or pcDNA-CD38 by electroporation using the Amaxa solution L kit. For
knockdown of CD38 or PPARg, 3T3-L1 adipocytes were transfected with
50 nM CD38 small interfering RNA (siRNA), 50 nM PPARg siRNA, or 50 nM
control siRNA (Santa Cruz Biotechnology) using a DeliverX plus siRNA trans-
fection kit (Panomics, Fremont, CA, USA) specially designed for differentiated
3T3-L1 adipocytes and cultured for 48 hr for analysis.
Measurement of Intracellular Calcium Concentration
3T3-L1 adipocytes were plated onto Matrigel-coated coverslips after single
cell dissociation with Accutase (Sigma-Aldrich, St. Louis, MO, USA) and
loaded with Fura-2 acetoxymethyl ester (Molecular Probes, Eugene, OR,
USA). Coverslips were mounted on a laminar flow perfusion chamber (Live
Cell Instrument, Seoul, Korea). Collection of images of Fura-2-loaded cells1618 Cell Reports 2, 1607–1619, December 27, 2012 ª2012 The Autand determination of intracellular calcium concentration were performed as
described in Extended Experimental Procedures.
Western Blot Analysis
Western blot was performed according to the standard procedures described
in Extended Experimental Procedures.
Statistical Analysis
Data are presented as means ± SEM. Statistical significance was determined
using a two-tailed Student’s t test and one-way ANOVA test followed by
Scheffe’s post hoc test.
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